YZG-331

Pharmaceutical compound From Wikipedia, the free encyclopedia

YZG-331, also known as N6-[(S)-1-(phenyl)propyl]adenosine, is an adenosine receptor agonist which is or was under investigation for the potential treatment of insomnia.[1][2][3]

Other namesN6-[(S)-1-(Phenyl)propyl]adenosine
Drug classAdenosine receptor agonist; Sedative; Hypnotic
ATC code
  • None
PubChem CID
Quick facts Clinical data, Other names ...
YZG-331
Clinical data
Other namesN6-[(S)-1-(Phenyl)propyl]adenosine
Drug classAdenosine receptor agonist; Sedative; Hypnotic
ATC code
  • None
Identifiers
  • (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(1S)-1-phenylpropyl]amino]purin-9-yl]oxolane-3,4-diol
PubChem CID
Chemical and physical data
FormulaC19H23N5O4
Molar mass385.424 g·mol−1
3D model (JSmol)
  • CC[C@@H](C1=CC=CC=C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
  • InChI=1S/C19H23N5O4/c1-2-12(11-6-4-3-5-7-11)23-17-14-18(21-9-20-17)24(10-22-14)19-16(27)15(26)13(8-25)28-19/h3-7,9-10,12-13,15-16,19,25-27H,2,8H2,1H3,(H,20,21,23)/t12-,13+,15+,16+,19+/m0/s1
  • Key:RRRLUFHDFDNPMZ-BPAMBQHCSA-N
Close

Pharmacology

The drug appears to act through the adenosine A1 and A2A receptors.[3] It produces sedative and hypnotic effects and hypolocomotion in animals.[3] The drug is orally active and crosses the blood–brain barrier, although its intestinal absorption and central permeability may be reduced by its P-glycoprotein substrate activity.[4][5] It is a synthetic derivative of adenosine and of N6-(4-hydroxybenzyl)adenine riboside (NHBA).[5][3] The latter compound is found in the traditional Chinese medicinal herb Gastrodia elata.[5][3]

Development

YZG-331 was first described in the scientific literature by at least 2014.[6] As of 2025, it has reached the preclinical research stage of development.[1]

See also

References

Related Articles

Wikiwand AI